Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk-Reference-Cited by-同舟云学术

Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk

Published:2014-08-06 Issue:248 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Moeckel Douglas¹,Jeong Soon Soeg²,Sun Xiaofeng³,Broekman M. Johan⁴⁵,Nguyen Annie¹,Drosopoulos Joan H. F.⁴⁵,Marcus Aaron J.⁴⁵,Robson Simon C.³,Chen Ridong²,Abendschein Dana¹

Affiliation:

1. Center for Cardiovascular Research, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

2. APT Therapeutics Inc., 4041 Forest Park Avenue, St. Louis, MO 63108, USA.

3. Division of Gastroenterology/Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

4. Thrombosis Research Laboratory, Research Service, Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA.

5. Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10021, USA.

Abstract

APT102, an optimized human apyrase designed for treatment of myocardial infarction, improves recanalization of occluded arteries and decreases heart muscle damage, without an increased bleeding risk.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference51 articles.

1. Executive Summary: Heart Disease and Stroke Statistics—2013 Update

2. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;Kushner F. G.;Circulation,2009

3. Aspirin Resistance and Atherothrombotic Disease

4. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use

5. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Milk-derived haem scavenging microsponges protect heart against ferroptosis-induced reperfusion injury;2024-06-20

2. Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo‐Controlled Study;Journal of the American Heart Association;2024-06-04

3. Exploring the Role of Platelets in Virus-Induced Inflammatory Demyelinating Disease and Myocarditis;International Journal of Molecular Sciences;2024-03-19

4. Heterologous expression and biochemical characterization of the recombinant nucleoside triphosphate diphosphohydrolase 2 (LbNTPDase2) from Leishmania (Viannia) braziliensis;Purinergic Signalling;2023-11-24

5. Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment;Diabetes;2023-08-25